[HTML][HTML] Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of hematology & oncology, 2017 - Springer
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - infona.pl
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
[引用][C] Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - cir.nii.ac.jp
Emerging therapies for acute myeloid leukemia | CiNii Research CiNii 国立情報学研究所 学術
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
[HTML][HTML] Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & …, 2017 - jhoonline.biomedcentral.com
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Emerging therapies for acute myeloid leukemia.
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - europepmc.org
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & Oncology (Web), 2017 - jglobal.jst.go.jp
Emerging therapies for acute myeloid leukemia | Article Information | J-GLOBAL Art J-GLOBAL
ID:201802256870917928 Reference number:18A1141204 Emerging therapies for acute …
ID:201802256870917928 Reference number:18A1141204 Emerging therapies for acute …
Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of hematology & …, 2017 - pubmed.ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Emerging therapies for acute myeloid leukemia.
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - search.ebscohost.com
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
[HTML][HTML] Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Emerging therapies for acute myeloid leukemia
C Saygin, HE Carraway - Journal of Hematology & Oncology, 2017 - search.proquest.com
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …